CIK 0001091596 · Non-accelerated filer<br>Smaller reporting company
Nuo Therapeutics, Inc.
Sign in to watch- Ticker
- AURX
- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 233011702
- Phone
- 832-236-9060
- Business address
- 8285 EL RIO, SUITE 190, HOUSTON, TX, 77054
- Former names
- Nuo Therapeutics, Inc, CYTOMEDIX INC, AUTOLOGOUS WOUND THERAPY INC, AUTOLOGOUS WOUND TRERAPY INC
- Open-market buys, last 90 days
- $9,539
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,539. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2010-06-08 | JORDEN DAVID EMERSON Director | Purchase | +23,100 | $0.48 | $11K | 4,345,100 |
| 2010-05-20 | JORDEN DAVID EMERSON Director | Purchase | +16,000 | $0.62 | $10K | 4,322,000 |
| 2010-05-18 | JORDEN DAVID EMERSON Director | Purchase | +206,000 | $0.63 | $130K | 4,306,000 |
| 2010-04-29 | JORDEN DAVID EMERSON Director | Purchase | +25,000 | $0.72 | $18K | 4,100,000 |
| 2010-04-28 | JORDEN DAVID EMERSON Director | Purchase | +14,000 | $0.72 | $10K | 4,075,000 |
| 2010-04-16 | JORDEN DAVID EMERSON Director | Purchase | +22,270 | $0.59 | $13K | 4,061,000 |
| 2010-04-14 | JORDEN DAVID EMERSON Director | Purchase | +32,310 | $0.56 | $18K | 4,038,730 |
| 2010-04-13 | JORDEN DAVID EMERSON Director | Purchase | +100,000 | $0.56 | $56K | 4,006,420 |
| 2010-04-13 | JORDEN DAVID EMERSON Director | Purchase | +100,000 | $0.56 | $56K | 4,421,474 |
| 2010-04-09 | JORDEN DAVID EMERSON Director | Purchase · 10% Series D Convertible Preferred Stock | +0 | 473,044 | ||
| 2010-04-09 | JORDEN DAVID EMERSON Director | Purchase · Common Stock | +0 | 744,726 | ||
| 2010-04-09 | Maslan Andrew Scott Chief Financial Officer | Purchase · 10% Series D Convertible Stock | +0 | 367,321 | ||
| 2010-04-09 | Maslan Andrew Scott Chief Financial Officer | Purchase · Common Stock Warrants | +0 | 376,282 | ||
| 2010-04-09 | ROSENDALE MARTIN P Chief Executive Officer | Purchase · 10% Series D Convertible Preferred Stock | +0 | 926,259 | ||
| 2010-04-09 | ROSENDALE MARTIN P Chief Executive Officer | Purchase · Common Stock Warrants | +0 | 944,181 | ||
| 2010-04-09 | JORDEN DAVID EMERSON Director | Purchase · 10% Series D Convertible Preferred Stock | +0 | 4,049,789 | ||
| 2010-04-09 | JORDEN DAVID EMERSON Director | Purchase · Common Stock | +0 | 4,321,474 | ||
| 2010-02-25 | McLoughlin Mark T Director | Grant or award · Nonqualified option to purchase common stock | +40,000 | 276,667 | ||
| 2010-02-25 | KEITH STEPHEN Director | Grant or award · Nonqualified options to purchase common stock | +40,000 | 80,000 | ||
| 2010-02-25 | WINZER C ERIC Director | Grant or award · Nonqualified option to purchase common stock | +40,000 | 80,000 |
Page 20 of 22 · 436 trades